Japanese Biotechs Promote "Relationship Building" In Developing Marketing Deals
This article was originally published in PharmAsia News
Executive Summary
Building solid relationships with licensing partners is key to sustaining and expanding those alliances in the long term, Eisai VP-Business Development Alex Scott said during a May 8 panel discussion at the Biotechnology Industry Organization International Convention in Boston
You may also be interested in...
Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.
Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.
Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.